Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules

10.1371/journal.pone.0154316

Saved in:

Bibliographic Details
Main Authors:	Sutiman N., Zhang Z., Ang M.K., Tan S.-W.D., Toh C.K., Ng Q.S., Chowbay B., Lim W.-T.
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	2019
Subjects:	erlotinib navelbine antineoplastic agent OSI-420 quinazoline derivative vinblastine vinorelbine tartrate adult advanced cancer aged alopecia anemia anorexia area under the curve arthralgia Article cancer fatigue clinical article clinical effectiveness constipation controlled study diarrhea dizziness drug dose escalation drug efficacy drug response drug safety drug tolerability dry eye dry skin dysphagia face pain febrile neutropenia female heartburn human hyponatremia infection keratitis loss of appetite male maximum plasma concentration myalgia nail disease nausea neuropathy neutropenia non small cell lung cancer nose disease outcome assessment paronychia phase 1 clinical trial pruritus rash steady state stomatitis vomiting analogs and derivatives Carcinoma, Non-Small-Cell Lung clinical trial drug administration middle aged treatment outcome Adult Aged Antineoplastic Combined Chemotherapy Protocols Drug Administration Schedule Erlotinib Hydrochloride Female Humans Male Middle Aged Quinazolines Treatment Outcome Vinblastine
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/161571
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-161571
record_format	dspace
spelling	sg-nus-scholar.10635-1615712023-09-21T08:24:27Z Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules Sutiman N. Zhang Z. Ang M.K. Tan S.-W.D. Toh C.K. Ng Q.S. Chowbay B. Lim W.-T. DUKE-NUS MEDICAL SCHOOL DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) erlotinib navelbine antineoplastic agent erlotinib OSI-420 quinazoline derivative vinblastine vinorelbine tartrate adult advanced cancer aged alopecia anemia anorexia area under the curve arthralgia Article cancer fatigue clinical article clinical effectiveness constipation controlled study diarrhea dizziness drug dose escalation drug efficacy drug response drug safety drug tolerability dry eye dry skin dysphagia face pain febrile neutropenia female heartburn human hyponatremia infection keratitis loss of appetite male maximum plasma concentration myalgia nail disease nausea neuropathy neutropenia non small cell lung cancer nose disease outcome assessment paronychia phase 1 clinical trial pruritus rash steady state stomatitis vomiting analogs and derivatives Carcinoma, Non-Small-Cell Lung clinical trial drug administration middle aged treatment outcome Adult Aged Antineoplastic Combined Chemotherapy Protocols Carcinoma, Non-Small-Cell Lung Drug Administration Schedule Erlotinib Hydrochloride Female Humans Male Middle Aged Quinazolines Treatment Outcome Vinblastine 10.1371/journal.pone.0154316 PLoS ONE 11 5 e0154316 2019-11-06T07:57:34Z 2019-11-06T07:57:34Z 2016 Article Sutiman N., Zhang Z., Ang M.K., Tan S.-W.D., Toh C.K., Ng Q.S., Chowbay B., Lim W.-T. (2016). Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules. PLoS ONE 11 (5) : e0154316. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0154316 19326203 https://scholarbank.nus.edu.sg/handle/10635/161571 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20191101
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	erlotinib navelbine antineoplastic agent erlotinib OSI-420 quinazoline derivative vinblastine vinorelbine tartrate adult advanced cancer aged alopecia anemia anorexia area under the curve arthralgia Article cancer fatigue clinical article clinical effectiveness constipation controlled study diarrhea dizziness drug dose escalation drug efficacy drug response drug safety drug tolerability dry eye dry skin dysphagia face pain febrile neutropenia female heartburn human hyponatremia infection keratitis loss of appetite male maximum plasma concentration myalgia nail disease nausea neuropathy neutropenia non small cell lung cancer nose disease outcome assessment paronychia phase 1 clinical trial pruritus rash steady state stomatitis vomiting analogs and derivatives Carcinoma, Non-Small-Cell Lung clinical trial drug administration middle aged treatment outcome Adult Aged Antineoplastic Combined Chemotherapy Protocols Carcinoma, Non-Small-Cell Lung Drug Administration Schedule Erlotinib Hydrochloride Female Humans Male Middle Aged Quinazolines Treatment Outcome Vinblastine
spellingShingle	erlotinib navelbine antineoplastic agent erlotinib OSI-420 quinazoline derivative vinblastine vinorelbine tartrate adult advanced cancer aged alopecia anemia anorexia area under the curve arthralgia Article cancer fatigue clinical article clinical effectiveness constipation controlled study diarrhea dizziness drug dose escalation drug efficacy drug response drug safety drug tolerability dry eye dry skin dysphagia face pain febrile neutropenia female heartburn human hyponatremia infection keratitis loss of appetite male maximum plasma concentration myalgia nail disease nausea neuropathy neutropenia non small cell lung cancer nose disease outcome assessment paronychia phase 1 clinical trial pruritus rash steady state stomatitis vomiting analogs and derivatives Carcinoma, Non-Small-Cell Lung clinical trial drug administration middle aged treatment outcome Adult Aged Antineoplastic Combined Chemotherapy Protocols Carcinoma, Non-Small-Cell Lung Drug Administration Schedule Erlotinib Hydrochloride Female Humans Male Middle Aged Quinazolines Treatment Outcome Vinblastine Sutiman N. Zhang Z. Ang M.K. Tan S.-W.D. Toh C.K. Ng Q.S. Chowbay B. Lim W.-T. Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules
description	10.1371/journal.pone.0154316
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Sutiman N. Zhang Z. Ang M.K. Tan S.-W.D. Toh C.K. Ng Q.S. Chowbay B. Lim W.-T.
format	Article
author	Sutiman N. Zhang Z. Ang M.K. Tan S.-W.D. Toh C.K. Ng Q.S. Chowbay B. Lim W.-T.
author_sort	Sutiman N.
title	Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules
title_short	Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules
title_full	Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules
title_fullStr	Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules
title_full_unstemmed	Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules
title_sort	phase i study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (nsclc) using two different schedules
publishDate	2019
url	https://scholarbank.nus.edu.sg/handle/10635/161571
_version_	1778169211753857024

Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules

Similar Items